Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 851 to 860 of 996 total matches.

Opioids for Pain

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
: a randomized clinical trial. JAMA 2017; 318:1661. 4. R Chou et al. Treatments for acute pain: a systematic ...
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Med Lett Drugs Ther. 2022 Dec 12;64(1665):193-200 |  Show IntroductionHide Introduction

Cord Blood Banks

   
The Medical Letter on Drugs and Therapeutics • Oct 01, 2001  (Issue 1114)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D., Oregon ...
Pregnant women now often receive promotional material from private cord blood banks urging them to save and store their babies' cord blood.
Med Lett Drugs Ther. 2001 Oct 1;43(1114):84-6 |  Show IntroductionHide Introduction

Three New Drugs for Hyperlipidemia

   
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003  (Issue 1151)
, Copenhagen; Dan M. Roden, M.D., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Med Lett Drugs Ther. 2003 Mar 3;45(1151):17-9 |  Show IntroductionHide Introduction

Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003  (Issue 1158)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Elizabeth Stephens, M.D., Oregon Health ...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 |  Show IntroductionHide Introduction

Drug Interactions with Grapefruit Juice

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2004  (Issue 1173)
. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York University School ...
The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).
Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 |  Show IntroductionHide Introduction

Two New Drugs for Colon Cancer

   
The Medical Letter on Drugs and Therapeutics • Jun 07, 2004  (Issue 1184)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D ...
Cetuximab (Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab (Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan (Camptosar)when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved...
Med Lett Drugs Ther. 2004 Jun 7;46(1184):46-8 |  Show IntroductionHide Introduction

Tinidazole (Tindamax) - A New Anti-Protozoal Drug

   
The Medical Letter on Drugs and Therapeutics • Aug 30, 2004  (Issue 1190)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba; Neal H. Steigbigel, M.D., New York ...
Tinidazole (Tindamax - Presutti Labs), an oral antiprotozoal drug similar to metronidazole (Flagyl, and others), has been approved by the FDA for treatment of trichomoniasis in adults and for treatment of giardiasis, intestinal amebiasis and amebic liver abcess in adults and children more than 3 years old. Tinidazole has been widely used outside of the US for decades under the trade name Fasigyn (Pfizer).
Med Lett Drugs Ther. 2004 Aug 30;46(1190):70-2 |  Show IntroductionHide Introduction

Duloxetine (Cymbalta): A New SNRI for Depression

   
The Medical Letter on Drugs and Therapeutics • Oct 11, 2004  (Issue 1193)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Duloxetine hydrochloride (Cymbalta - Lilly), a selective serotonin and norepinephrine reuptake inhibitor (SNRI), has been approved by the FDA for treatment of major depressive disorder in adults, and more recently for diabetic peripheral neuropathy as well. The Medical Letter will review its role in diabetic neuropathy in a future issue.
Med Lett Drugs Ther. 2004 Oct 11;46(1193):81-3 |  Show IntroductionHide Introduction

Acamprosate (Campral) for Alcoholism

   
The Medical Letter on Drugs and Therapeutics • Jan 03, 2005  (Issue 1199)
, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University ...
Acamprosate calcium (Campral - Forest) is now being marketed for oral use to maintain abstinence from alcohol. It has been used in France and other countries since 1989.
Med Lett Drugs Ther. 2005 Jan 3;47(1199):1-3 |  Show IntroductionHide Introduction

Alprazolam (Xanax, and others) Revisited

   
The Medical Letter on Drugs and Therapeutics • Jan 17, 2005  (Issue 1200)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle R. Simons ...
Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR, which can be taken once a day, recently became available for panic disorder.
Med Lett Drugs Ther. 2005 Jan 17;47(1200):5-7 |  Show IntroductionHide Introduction